Liver Cancer

Opdivo (nivolumab) given in combination with Yervoy (ipilimumab) is now approved by the Food and Drug Administration (FDA) for the treatment of patients with liver cancer, or hepatocellular carcinoma (HCC), who have already been treated with the chemotherapy drug sorafenib.

The combination of Lenvima (lenvatinib), an oral kinase inhibitor, and the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, showed promising benefits for the treatment of patients with liver cancer (or hepatocellular carcinoma) that cannot be removed by surgery (unresectable).

In May 2020, the FDA approved the combination of 2 immunotherapies for patients with metastatic hepatocellular carcinoma (liver cancer) who have not received systemic therapy and cannot be treated by surgery.

Maria Falzone is a comedian and creator of “SEX RULES” talk, who is facing a rare and terminal liver cancer. She wants to be remembered as the person who changed the conversation around sex and sexuality.

Previously approved for thyroid cancer and kidney cancer, the FDA has recently approved Lenvima as the first treatment for patients with liver cancer.

In 2017, the FDA approved two new treatments for patients with hepatocellular carcinoma (HCC), Stivarga and Opdivo. Read about these new treatments for liver cancer.

Unlike many types of cancers, the number of new cases of liver cancer, specifically hepatocellular carcinoma—the most common type of liver cancer—is increasing in the US. Read about the pressures, including the unmet needs, of caregivers of those affected by liver cancer.

Lori Plutchak is part of a unique kind of cancer support group: the Team Survivor San Diego Sea Dragons boat racing team, which is made up of nearly 40 cancer survivors.